Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

June 29, 2026 updated by: Ocular Therapeutix, Inc.

A Phase 3b, Multicenter, Open-Label, Extension Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

850

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • California
      • Bakersfield, California, United States, 93309
        • Recruiting
        • California Retina Consultants (CRC)
        • Contact:
        • Principal Investigator:
          • Dilsher Dhoot, MD
      • Santa Barbara, California, United States, 93103
        • Recruiting
        • California Retina Consultants (CRC)
        • Contact:
    • Connecticut
      • Waterford, Connecticut, United States, 06385
        • Recruiting
        • Retina Group of New England
        • Contact:
        • Principal Investigator:
          • Nauman A Chaudhry, MD
    • Florida
      • Fort Lauderdale, Florida, United States, 33308
        • Recruiting
        • Retina Group of Florida - Fort Lauderdale
        • Principal Investigator:
          • Eduardo Uchiyama, MD
        • Contact:
    • Maryland
      • Hagerstown, Maryland, United States, 21740
        • Recruiting
        • Mid Atlantic Retina Specialists
        • Principal Investigator:
          • Adam Gerstenblith, MD
        • Contact:
      • Hagerstown, Maryland, United States, 21740
        • Recruiting
        • Cumberland Valley Retina Associates
        • Principal Investigator:
          • Allen Hu, MD
        • Contact:
    • South Carolina
      • West Columbia, South Carolina, United States, 29619
        • Recruiting
        • Palmetto Retina Center
        • Contact:
        • Principal Investigator:
          • Nitin Nigam, MD
    • Texas
      • Austin, Texas, United States, 78705
        • Recruiting
        • Austin Retina Associates
        • Contact:
          • Robert William Wong, MD
          • Phone Number: 512-451-0103
        • Principal Investigator:
          • Robert William Wong, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participants with a diagnosis of nAMD in the study eye who successfully completed Study OTX-TKI-2023-AMD-301 through Week 104 or Study OTX-TKI-2023-AMD-303 through Week 96
  • Have adequate ocular media and adequate pupillary dilation in the study eye to permit good quality fundus imaging
  • Are able and willing to comply with all study requirements and visits
  • Have provided written informed consent

Exclusion Criteria:

  • Have significant intraocular or periocular infection (bacterial, viral, or fungal) in the study eye within 3 months prior to Day 1
  • History of intraocular inflammation in the study eye
  • Have evidence of a rhegmatogenous retinal detachment or visually significant/severe epiretinal membrane, macular hole, tear of the retinal pigment epithelium in the macula, or other macular
  • Presence of an intercurrent illness or condition that in the opinion of the Investigator, may place the participant at an unacceptable risk, preventing the participant from completing the study or confound the interpretation of study results
  • Female participants who are pregnant (had a positive urine test at the Baseline visit [Day 1]) or breastfeeding or intend to become pregnant during the study, who are unwilling to use 2 forms of highly effective contraception from baseline until they exit the study or at least 3 months after the last study treatment, whichever is later.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: OTX-TKI
Drug: OTX-TKI
Intravitreal Injection of OTX-TKI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence and severity of treatment-emergent adverse events (TEAEs) from Baseline (Day 1) through Week 144
Time Frame: from Baseline (Day 1) through Week 144
Number of events
from Baseline (Day 1) through Week 144
Proportion of participants with severe vision loss (defined as ≥ 30 Early Treatment Diabetic Retinopathy Study [ETDRS] letters loss) from Baseline (Day 1) through Week 144
Time Frame: from Baseline (Day 1) through Week 144
Percentage
from Baseline (Day 1) through Week 144

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ocular Therapeutix, Inc.

Collaborators

Fortrea
Duke Reading Center

Investigators

  • Principal Investigator: Dilsher Dhoot, MD, California Retina Consultants (CRC)-Bakersfield

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 27, 2026

Primary Completion (Estimated)

August 1, 2030

Study Completion (Estimated)

August 1, 2030

Study Registration Dates

First Submitted

March 31, 2026

First Submitted That Met QC Criteria

March 31, 2026

First Posted (Actual)

April 7, 2026

Study Record Updates

Last Update Posted (Actual)

July 1, 2026

Last Update Submitted That Met QC Criteria

June 29, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • OTX-TKI-2025-AMD-301
  • SOL-X (Other Identifier: Ocular Therapeutix, Inc.)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe